Coherus Oncology (CHRS) Interest Expenses (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Interest Expenses data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 75.06% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (up 4.68% YoY), and the FY2025 full-year result was $368.1 million, down 10.83% from the prior year.
• Interest Expenses slipped to $2.2 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $29.9 million in Q4 2022 to a low of $1.9 million in Q4 2024.
• A 5-year average of $7.3 million and a median of $6.6 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 242.14% in 2022 and slumped 81.99% in 2024, its largest moves.
• Tracing CHRS's Interest Expenses over 5 years: stood at $29.9 million in 2022, then plunged by 64.47% to $10.6 million in 2023, then tumbled by 81.99% to $1.9 million in 2024, then gained by 17.63% to $2.2 million in 2025, then slipped by 2.8% to $2.2 million in 2026.
• Business Quant data shows CHRS's Interest Expenses at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.7 million in Q3 2025.